Partnering for Precision: CDx Development for Antibody-Drug Conjugates

Webinar preview

As antibody-drug conjugates (ADCs) advance in precision oncology, diagnostics play a vital role in identifying eligible patients, validating biomarkers and supporting regulatory approval.

Companion diagnostics (CDx) enable targeted therapies by confirming the presence of specific biomarkers, helping to match patients with the most appropriate treatments. A well-integrated diagnostic strategy ensures that ADC development is optimized for clinical success and regulatory readiness.

In this webinar, Dr. Yuri Fesko will explore the expanding role of precision diagnostics in ADC development and how strategic diagnostic partnerships can help streamline biomarker validation, patient selection and regulatory alignment.

Who Should Attend?

This webinar is ideal for professionals in the pharmaceutical industry, particularly oncology researchers involved in ADC drug development and precision medicine. Key attendees include:

• Pharma industry professionals focused on ADCs
• Clinical researchers and diagnostic development teams engaged in clinical trials and biomarker research
• Decision-makers and strategists seeking to enhance their understanding of biomarker-driven therapies and their impact on drug development

What You Will Learn

Attendees will learn about:

• Key considerations in antigen validation and patient selection
• The role of CDx in ADC programs
• How to support biomarker-driven therapy development